[Predicting response to therapy in breast cancer]

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Breast cancer classification traditionally relies on histopathology.
• Gene expression profiling offers molecular subtyping (luminal A/B, HER2, basal).
• These subtypes exhibit distinct prognoses and treatment responses.

Purpose of the Study:

• To explore the utility of gene expression profiles for breast cancer staging.
• To evaluate prognostic and predictive tools for adjuvant therapy selection.
• To optimize patient selection for chemotherapy, particularly in estrogen-receptor-positive cases.

Main Methods:

• Utilizing microarray technologies for gene expression profiling.
• Examining established genomic tools such as the 21-gene recurrence score (Oncotype DX) and the 70-gene profile (MammaPrint).
• Comparing genomic data with traditional histopathological parameters.

Main Results:

• Gene expression profiles effectively distinguish four key breast cancer subtypes.
• Prognostic and predictive information from genomic tools aids in treatment decisions.
• Genomic approaches provide objective data beyond traditional markers.

Conclusions:

• Molecular staging via gene expression profiling enhances breast cancer classification.
• Genomic decision-making tools improve the targeting of adjuvant therapies.
• These approaches can lead to more rational treatment choices and avoid unnecessary chemotherapy.